Terms: = Germ cell tumor AND NTRK1, ENSG00000198400, 4914, P04629, TRK1, MTC, DKFZp781I14186, p140-TrkA, TRKA, TRK AND Treatment
869 results:
1. [Not Available].
Ciappuccini R; Nascimento C; Edet-Sanson A; Bardet S
Bull Cancer; 2024 Oct; 111(10S1):10S64-10S72. PubMed ID: 39505438
[TBL] [Abstract] [Full Text] [Related]
2. Management of medullary thyroid cancer based on variation of carcinoembryonic antigen and calcitonin.
Wang B; Huang J; Chen L
Front Endocrinol (Lausanne); 2024; 15():1418657. PubMed ID: 39449744
[TBL] [Abstract] [Full Text] [Related]
3. Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies.
Huai JX; Wang F; Zhang WH; Lou Y; Wang GX; Huang LJ; Sun J; Zhou XQ
Front Endocrinol (Lausanne); 2024; 15():1484815. PubMed ID: 39439561
[TBL] [Abstract] [Full Text] [Related]
4. Photosensitizing metal-organic framework nanoparticles combined with tumor-sensitization strategies can enhance the phototherapeutic effect upon medullary thyroid carcinoma.
Feng Y; Jiang Q; Ma X; Sun H; Chai Y; Li X; Wang Z; Feng F
Biochim Biophys Acta Gen Subj; 2024 Dec; 1868(12):130725. PubMed ID: 39433228
[TBL] [Abstract] [Full Text] [Related]
5. Unusual Presentation of Metastatic Medullary Thyroid Cancer Involving Bone Marrow, Kidneys, and Adrenal Gland: A Literature Review Based on a Case Report.
Ebrahimi P; Payab M; Shariati A; Alipour N; Nozheh A; Tavangar SM; Taheri H; Ebrahimpur M
Cancer Rep (Hoboken); 2024 Oct; 7(10):e70022. PubMed ID: 39410877
[TBL] [Abstract] [Full Text] [Related]
6. ERK signaling promotes resistance to trk kinase inhibition in Ntrk fusion-driven glioma mouse models.
Schmid S; Russell ZR; Yamashita AS; West ME; Parrish AG; Walker J; Rudoy D; Yan JZ; Quist DC; Gessesse BN; Alvinez N; Hill KD; Anderson LW; Cimino PJ; Kumasaka DK; Parchment RE; Holland EC; Szulzewsky F
Cell Rep; 2024 Oct; 43(10):114829. PubMed ID: 39365700
[TBL] [Abstract] [Full Text] [Related]
7. Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Zhang Y; Zheng WH; Zhou SH; Gu JL; Yu Q; Zhu YZ; Yan YJ; Zhu Z; Shang JB
Cell Commun Signal; 2024 Sep; 22(1):460. PubMed ID: 39342195
[TBL] [Abstract] [Full Text] [Related]
8. Long-Term tumor Stability After First-Line treatment With Larotrectinib in an Infant With Ntrk2 Fusion-Positive High-Grade Glioma.
Simoneau J; Robertson P; Muraszko K; Maher CO; Garton H; Calvert R; Koschmann C; Upadhyaya SA; Mody R; Brown N; Kumar-Sinha C; Parmar H; Camelo-Piragua S; Franson AT
J Natl Compr Canc Netw; 2024 Sep; 22(7):. PubMed ID: 39236755
[TBL] [Abstract] [Full Text] [Related]
9. Simultaneous occurrence of papillary thyroid carcinoma, medullary thyroid carcinoma, and lymphoma: A case report.
Hao Z; Cui H; Li Y; Wu W; Wang Y; Dan H; Lou L; Wang H; Zhao P
Medicine (Baltimore); 2024 Aug; 103(33):e39363. PubMed ID: 39151514
[TBL] [Abstract] [Full Text] [Related]
10. Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib.
Gambale C; Prete A; Romei C; Celi A; Elisei R; Matrone A
Eur Thyroid J; 2024 Oct; 13(5):. PubMed ID: 39136571
[TBL] [Abstract] [Full Text] [Related]
11. A practical nomogram for preoperatively predicting lateral cervical lymph node metastasis in medullary thyroid carcinoma: a dual-center retrospective study.
Zhu J; Guo T; Guo S; Chang L; Zhao J; Wang X; Wei X
Front Endocrinol (Lausanne); 2024; 15():1349853. PubMed ID: 39129917
[TBL] [Abstract] [Full Text] [Related]
12. Durability of Response With Selpercatinib in Patients With
Wirth LJ; Brose MS; Subbiah V; Worden F; Solomon B; Robinson B; Hadoux J; Tomasini P; Weiler D; Deschler-Baier B; Tan DSW; Maeda P; Lin Y; Singh R; Bayt T; Drilon A; Cassier PA
J Clin Oncol; 2024 Sep; 42(27):3187-3195. PubMed ID: 39094065
[No Abstract] [Full Text] [Related]
13. Biomarker identification of medullary thyroid carcinoma from gene expression profiles considering without-treatment and with-treatment studies-A bioinformatics approach.
Loganathan T; George Priya Doss C
Adv Protein Chem Struct Biol; 2024; 142():367-396. PubMed ID: 39059991
[TBL] [Abstract] [Full Text] [Related]
14. Atypical cellular responses mediated by intracellular constitutive active trkB (Ntrk2) kinase domains and a solely intracellular Ntrk2-fusion oncogene.
Gupta R; Dittmeier M; Wohlleben G; Nickl V; Bischler T; Luzak V; Wegat V; Doll D; Sodmann A; Bady E; Langlhofer G; Wachter B; Havlicek S; Gupta J; Horn E; Lüningschrör P; Villmann C; Polat B; Wischhusen J; Monoranu CM; Kuper J; Blum R
Cancer Gene Ther; 2024 Sep; 31(9):1357-1379. PubMed ID: 39039193
[TBL] [Abstract] [Full Text] [Related]
15. Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).
Leboulleux S; Kapiteijn E; Litière S; Schöffski P; Godbert Y; Rodien P; Jarzab B; Salvatore D; Zanetta S; Capdevila J; Bastholt L; De La Fouchardiere C; Lalami Y; Bardet S; Cornélis F; Dedecjus M; Links T; Sents W; Schlumberger M; Locati DL; Newbold K
Front Endocrinol (Lausanne); 2024; 15():1403687. PubMed ID: 39015176
[TBL] [Abstract] [Full Text] [Related]
16. Ntrk-fused central nervous system tumours: clinicopathological and genetic insights and response to trk inhibitors.
Kim EE; Park CK; Kim SK; Phi JH; Paek SH; Choi JY; Kang HJ; Lee JH; Won JK; Yun H; Park SH
Acta Neuropathol Commun; 2024 Jul; 12(1):118. PubMed ID: 39014476
[TBL] [Abstract] [Full Text] [Related]
17. The Multi-Institutional Medullary Thyroid Cancer Collaborative Registry: Can a Rare tumor Registry Accurately Represent the Real-World Patient Population?
Szabo Yamashita T; Williams-Perez SM; Ehsan S; Mulder M; Kronenfeld D; Huang CY; Zhao H; Merriman K; Peterson SK; Hu MI; Zafereo M; Sosa JA; Grubbs EG
Thyroid; 2024 Sep; 34(9):1117-1125. PubMed ID: 38984944
[No Abstract] [Full Text] [Related]
18. Critically evaluated key points on hereditary medullary thyroid carcinoma.
Zhang D; Liang N; Sun H; Frattini F; Sui C; Yang M; Wang H; Dionigi G
Front Endocrinol (Lausanne); 2024; 15():1412942. PubMed ID: 38919477
[TBL] [Abstract] [Full Text] [Related]
19. The impact of preoperative calcitonin screening on the prognosis of patients with medullary thyroid cancer: a retrospective multicenter cohort study.
Hou Y; Yang Y; Chen G; Long J; He Y; Xiong D; Pang Y; Li Q; Dong G; Qiao S; Chen W; Li X; Zhang J; Xu T; Chen X; Lai F; Guan H; Lin B; Liu Y
Endocrine; 2024 Aug; 85(2):827-836. PubMed ID: 38834859
[TBL] [Abstract] [Full Text] [Related]
20. Primary resistance to selpercatinib in a patient with advanced medullary thyroid cancer.
Pitoia F; Trimboli P; Abelleira E
Endocrine; 2024 Oct; 86(1):109-113. PubMed ID: 38801596
[TBL] [Abstract] [Full Text] [Related]
[Next]